A carregar...
Antibodies to watch in 2013: Mid-year update
The transitions of antibody therapeutics to late-stage clinical development, regulatory review and the market are proceeding at a rapid pace in 2013. Since late 2012, two monoclonal antibody (mAb) therapeutics (itolizumab, trastuzumab emtansine) received their first approvals, first marketing applic...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Landes Bioscience
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3906304/ https://ncbi.nlm.nih.gov/pubmed/23727858 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.24990 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|